BioStem Technologies, Inc (BSEM) Fair Value & Analysis
Healthcare · US · Market cap $70.5M
BioStem Technologies, Inc
BSEM · US
Fair value as of: Jul 15, 2026
From 24 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $30.97 to $3.95 (−87.2%) since Jun 24, 2026. Share price −5.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $3.20 – $12.52 · fair‑value band $2.67 – $8.26 · the $3.86 price screens below the $3.95 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioStem Technologies, Inc (BSEM) currently trades at $3.86, while our model-based Fair Value estimate is $3.95 — implying the stock looks roughly 2.4% fairly valued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, BioStem Technologies, Inc generated revenue of $37.7M at a net margin of -51.3%. It earns a return on equity of -48.6%. Net debt stands at $4.5M. The stock trades on a trailing P/E of 4.7. Fundamentals as of Jul 15, 2026
Our scenario range runs from $2.67 (bear case) to $8.26 (bull case); at $3.86, the current price sits within that range. The share trades about 72% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at 2%, BSEM screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
BioStem Technologies, Inc reported revenue of $302M in FY2024 versus $2.5M in FY2020, a compound +230.8%/yr. Reported net income was $31.9M in FY2024.
Is BSEM fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioStem Technologies, Inc (BSEM) undervalued?
What is the fair value of BSEM?
What is the quality score of BSEM?
What is the revenue of BioStem Technologies, Inc (BSEM)?
What is the net profit margin of BSEM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BioStem Technologies, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.